A comment I wrote to "Dok Logic" on another board.
I agree. Your comment about Linda's description regarding the CONSISTENCY of cancer's response to DCVAX allowed me to connect a couple dots.
First of all, Linda Liau made a similar statement a while back about the amazing CONSISTENCY they are finding with respect to overall survival in GBM patients as this relates to DCVAX-L therapy. Percentages at 1 year, 2 years and so on.
Next, S.O.C. provides its own (albeit less efficacy) CONSISTENT response rate and overall survival rate in GBM cases.
Also, untreated GBM has its own very CONSISTENT overall survival statistics.
The point I am getting to is that CONSISTENT RESPONSES TO THERAPY seems to be a HALLMARK theme for GBM. Someone might say, "well look at IMUC," that was not consistent with their phase 1 trial. But I think, if you look at it from the proper perspective, they did have CONSISTENT results.
ICT-107 was very effective and CONSISTENT in the subclass of tumors that expressed a higher percentage of the antigens it was designed to attack. The problem is, by only selecting 6 antigens, the specific subclass population ICT-107 could affect in a small randomized double blind trial was luck of the draw. That's how it is with subclasses. Do you wonder why all those insiders sold before the results came out at IMUC? Yep, their drug was "high-brow," and they could not select "high-brow" tumors to match. The first phase allowed IMUC to select "high-brow" tumors. The phase 2 results do not mean ICT-107 did not work in those it was intended to help.
This brings me back to the concept of CONSISTENCY when it comes to GBM. With DCVAX, we are not relying on luck of the draw in the patient population. We are not trying to treat "high-brow" tumors, because we do not have a "high-brow" treatment. We have a "rainbow" treatment. Thus we should expect CONSISTENT response rates, pfs and os comparable to those found in previous clinical trials and compassionate use cases.
(Sorry for the homely analogy. I am not insinuating IMUC is prejudice against or for any HUMAN genetic predisposition.)
